Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.
Also called NCT02391337
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 161 participants
- Sponsor
- Registry
-
NCT02391337
-
- Other papers using this trial's data
- Consumer wearable devices for evaluation of heart rate control using digoxin versus beta-blockers: the RATE-AF randomized trial
- Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) randomised trial
- Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial
- Quantification and impact of circulating cardiotonic steroids in the RATE-AF randomised trial of patients with atrial fibrillation and heart failure
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02391337. Randomized; no masking; primary purpose treatment. Start 2016-12-20 (actual); primary completion 2019-04-15 (actual). Results posted on 2021-06-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
- Acronym
- RATE-AF
- Condition
- Permanent Atrial Fibrillation
- Intervention (Drug)
- Bisoprolol
- Intervention (Drug)
- Digoxin
- Lead sponsor
- University of Birmingham
Record details
- Record id
cardio:ct-nct02391337- Content hash
c7f0980a8ed1f1b1615b3f2974b8b467113392efbedae63ed37ad145e8c62dc8